Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -27.79 Million CNY | 15.33% |
| 2022 | -32.83 Million CNY | 4.89% |
| 2021 | -34.52 Million CNY | 12.16% |
| 2020 | -39.3 Million CNY | 16.7% |
| 2019 | -47.18 Million CNY | 13.9% |
| 2018 | -54.79 Million CNY | -178.14% |
| 2017 | -19.7 Million CNY | -31.66% |
| 2016 | -14.96 Million CNY | -229.39% |
| 2015 | -4.54 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -33.77 Million CNY | -21.49% |
| 2024 Q2 | -33.77 Million CNY | 5.16% |
| 2023 Q4 | -27.79 Million CNY | -186.49% |
| 2023 Q2 | -30.2 Million CNY | -190.69% |
| 2023 Q3 | 32.14 Million CNY | 206.43% |
| 2023 Q1 | 33.3 Million CNY | 201.43% |
| 2023 FY | -27.79 Million CNY | 15.33% |
| 2022 Q1 | 36.2 Million CNY | 204.88% |
| 2022 FY | -32.83 Million CNY | 4.89% |
| 2022 Q4 | -32.83 Million CNY | -193.31% |
| 2022 Q3 | 35.18 Million CNY | 203.21% |
| 2022 Q2 | -34.09 Million CNY | -194.17% |
| 2021 Q2 | -37.16 Million CNY | -188.6% |
| 2021 Q1 | 41.94 Million CNY | 206.72% |
| 2021 FY | -34.52 Million CNY | 12.16% |
| 2021 Q4 | -34.52 Million CNY | 0.0% |
| 2020 Q4 | -39.3 Million CNY | 0.0% |
| 2020 Q1 | 48.79 Million CNY | 203.42% |
| 2020 FY | -39.3 Million CNY | 16.7% |
| 2020 Q2 | -40.95 Million CNY | -183.94% |
| 2019 Q2 | -45.83 Million CNY | -183.65% |
| 2019 Q4 | -47.18 Million CNY | 0.0% |
| 2019 FY | -47.18 Million CNY | 13.9% |
| 2019 Q1 | 54.79 Million CNY | 200.0% |
| 2018 Q1 | 19.81 Million CNY | 0.0% |
| 2018 FY | -54.79 Million CNY | -178.14% |
| 2018 Q4 | -54.79 Million CNY | 0.0% |
| 2018 Q2 | -17.81 Million CNY | -189.92% |
| 2017 FY | -19.7 Million CNY | -31.66% |
| 2016 FY | -14.96 Million CNY | -229.39% |
| 2015 FY | -4.54 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 89.254% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 101.368% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 567.682% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 109.219% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -46.018% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 189.825% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 87.32% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 110.852% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 107.363% |
| SSY Group Limited | 1.71 Billion HKD | 101.622% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -275.713% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 108.238% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 100.055% |